PARP1 and cancer: Finally, these cells appear to be heavily dependent on PARP1/2 for DNA repair and treatment with the PARP1/2 inhibitor Olaparib results in synthetic lethality, suggesting that low KMT2C-expressing cancer cells are an attractive target for PARP1/2 inhibitor therapy (61).